Basic Information
| LncRNA/CircRNA Name | LINC00460 |
| Synonyms | NR_034119 |
| Region | GRCh38_13:106374477-106384315 |
| Ensemble | ENSG00000233532 |
| Refseq | NR_034119 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | osteosarcoma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, RIP, other |
| Sample | OS tissues and cell lines (Saos-2, HOS, U2OS and MG63) |
| Expression Pattern | up-regulated |
| Function Description | In this study, we found high linc00460 expression predicted poor prognosis of pan-cancer patients. Linc00460 was up-regulated in OS tissues and cells. High linc00460 expression was positively correlated with distant metastasis and poor overall survival of OS patients. Knockdown of linc00460 suppressed OS cells proliferation and metastasis in vitro. In addition, an inverse correlation between linc00460/miR-1224-5p and miR-1224-5p/FADS1 was observed in OS. Mechanistically, linc00460 functioned as a competitively endogenous RNA (ceRNA) to up-regulate FADS1 expression via sponging miR-1224-5p in OS, thereby promoting OS progression. |
| Pubmed ID | 31419446 |
| Year | 2019 |
| Title | Linc00460 Promotes Osteosarcoma Progression via miR-1224-5p/FADS1 Axis |
External Links
| Links for LINC00460 | GenBank HGNC NONCODE |
| Links for osteosarcoma | OMIM COSMIC |